U.S. markets closed

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.48-0.10 (-0.95%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
    GlobeNewswire

    Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

    CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 a.m. ET. A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. An archived replay will be available on the Company’s website for 90 days. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development. Please visit www.fulcrumtx.com. Contact:Christi WaarichDirector, Investor Relations and Corporate Communications617-651-8664cwaarich@fulcrumtx.com

  • A Look At Fulcrum Therapeutics' (NASDAQ:FULC) Share Price Returns
    Simply Wall St.

    A Look At Fulcrum Therapeutics' (NASDAQ:FULC) Share Price Returns

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...

  • Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates

    Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?